Eli Lilly (LLY) gains FDA approval for Foundayo, a weight loss pill, and acquires Centessa Pharmaceuticals for $7.8 billion to advance neurological treatments.

Eli Lilly and Company (LLY) received FDA approval for its weight loss pill, Foundayo, which can be taken without food or water restrictions, starting at $25 per month. The company also announced its acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on neurological treatments. These developments may enhance LLY's market position, particularly in the weight loss and neuroscience sectors. Investor sentiment is influenced by the dual impact of the weight loss pill and the strategic acquisition aimed at addressing complex medical conditions.

Eli Lilly (LLY) Receives FDA Approval for Weight Loss Pill, Acquires Centessa

AI Summary

Related News

Foxconn (2354) First-Quarter Revenue Jumps 30% Year-Over-Year

Bank of Nova Scotia (BNS) Maintains 4.6% Dividend Yield Since 1833

Tesla (TSLA) Q1 Deliveries Miss Estimates at 358,023 Vehicles

Eli Lilly (LLY) Acquires Centessa for $7.8 Billion